コンテンツへスキップ
Merck
  • Continuous veno-venous hemofiltration for massive rhabdomyolysis after malignant hyperthermia: report of 2 cases.

Continuous veno-venous hemofiltration for massive rhabdomyolysis after malignant hyperthermia: report of 2 cases.

Anesthesia progress (2013-03-20)
Shudong Fang, Hui Xu, Yesen Zhu, Hong Jiang
要旨

We present 2 cases of fulminant malignant hyperthermia (MH), complicated with massive rhabdomyolysis. The patients were successfully treated in the intensive care unit of our university teaching hospital, despite the lack of availability of dantrolene in our country, by early application of continuous veno-venous hemofiltration (CVVH). Both male patients developed fulminant malignant hyperthermia during anesthesia for oromaxillofacial surgery. CVVH was employed when the values of creatine phosphokinase (CPK), myoglobin (Mb), and lactate dehydrogenase (LDH) increased significantly. After emergency treatment and CVVH therapy, the values of CPK, Mb, and LDH in the blood plasma of the patients decreased significantly. The complications, including acute renal failure, disseminated intravascular coagulation, and acute respiratory distress syndrome were also treated without any obvious organ damage. Early detection and management are the keys to treat MH successfully. CVVH is a valuable therapeutic application in the initial/critical management of severe rhabdomyolysis. If these complications occur even with initial treatment with dantrolene, our experiences may be useful adjunctive treatments to consider.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
L-乳酸デヒドロゲナーゼ ウサギ筋肉由来, Type XI, lyophilized powder, 600-1,200 units/mg protein
Sigma-Aldrich
クレアチンホスホキナーゼ ウサギ筋肉由来, Type I, salt-free, lyophilized powder, ≥150 units/mg protein
Sigma-Aldrich
L-乳酸デヒドロゲナーゼ ウサギ筋肉由来, Type II, ammonium sulfate suspension, 800-1,200 units/mg protein
Sigma-Aldrich
L-乳酸デヒドロゲナーゼ ウシ心臓由来, Type III, ammonium sulfate suspension, ≥500 units/mg protein
Sigma-Aldrich
L-乳酸デヒドロゲナーゼ ウシ心臓由来, 1000 units/mL
Sigma-Aldrich
クレアチンホスホキナーゼ ウシ心臓由来, Type III, salt-free, lyophilized powder, ≥30 units/mg protein
Sigma-Aldrich
L-乳酸デヒドロゲナーゼ ウシ心臓由来, Type XVII, buffered aqueous glycerol solution, ≥400 units/mg protein
Sigma-Aldrich
L-乳酸デヒドロゲナーゼ ブタ心臓由来, ammonium sulfate suspension, ≥200 units/mg protein
Sigma-Aldrich
Lactic Dehydrogenase, recombinant 大腸菌由来, ≥90 U/mg
Sigma-Aldrich
L-乳酸デヒドロゲナーゼ ウシ筋肉由来, Type X, ammonium sulfate suspension, ≥600 units/mg protein